131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

NCT03649438 NO_LONGER_AVAILABLE

This expanded access is the best available therapy/compassionate use designed to determine the palliative benefit and toxicity of 131I-MIBG in patients with relapsed/refractory neuroblastoma or metastatic pheochromocytoma who are not eligible for therapies of higher priority. Patients may receive a range of doses depending on stem cell availability and tumor involvement of bone marrow. Response rate, toxicity, and time to progression and death will be evaluated.

Details

Lead sponsor	University of Texas Southwestern Medical Center
Status	NO_LONGER_AVAILABLE

Conditions

• Relapsed Neuroblastoma
• Metastatic Pheochromocytoma

Interventions

• 131 I-Metaiodobenzylguanidine
• Potassium Iodide
• G-csf

Countries

United States